Drug Profile
Rafabegron
Alternative Names: AD-9677; AJ-9677; TAK-677Latest Information Update: 30 Sep 2003
Price :
$50
*
At a glance
- Originator Dainippon Pharmaceutical
- Developer Dainippon Pharmaceutical; Takeda Pharmaceuticals North America
- Class Acetic acids; Antihyperglycaemics; Indoles; Small molecules
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 30 Sep 2003 Discontinued - Phase-II for Obesity in USA (unspecified route)
- 30 Sep 2003 Discontinued - Phase-II for Type-2 diabetes mellitus in Japan (PO)
- 30 Sep 2003 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)